Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q1 FY27 results · Apr–Jun 2026
Panacea Biotec reported revenue from operations of ₹199.57 crore (up 19.7% from Q1 FY26) and net profit of ₹2.20 crore (down 44.4% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 199.57 | 166.70 | +19.7% | 166.75 | +19.7% |
| Other income | 4.24 | 5.67 | −25.2% | 2.55 | +66.3% |
| Total income | 203.81 | 172.37 | +18.2% | 169.30 | +20.4% |
| Profit before tax | 3.57 | 6.56 | −45.6% | (1.25) | Turned profit |
| Net profit for the period | 2.20 | 3.96 | −44.4% | (1.00) | Turned profit |
| Attributable to shareholders of the company | 2.30 | 4.05 | −43.2% | 0.52 | +342.3% |
| EPS, basic (₹) | 0.38 | 0.66 | −42.4% | 0.08 | +375.0% |
| Net margin (%) | 1.1 | 2.4 | -0.6 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 134.71 | 112.25 | +20.0% | 111.12 | +21.2% |
| Other income | 6.06 | 4.95 | +22.4% | 5.60 | +8.2% |
| Total income | 140.77 | 117.20 | +20.1% | 116.72 | +20.6% |
| Profit before tax | 2.00 | (8.84) | Turned profit | (4.61) | Turned profit |
| Net profit for the period | 1.39 | (6.70) | Turned profit | (0.18) | Turned profit |
| EPS, basic (₹) | 0.23 | (1.09) | Turned profit | (0.03) | Turned profit |
| Net margin (%) | 1.0 | -6.0 | -0.2 |
Consolidated
- Filed with BSE
- 13 Aug 2026, 18:54 IST
- Board meeting
- 13 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2026, 18:54 IST
- Board meeting
- 13 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE